Enovis Corporation (ENOV)

Enovis Corp.'s stock price has fluctuated over the past six months. As of October 27, 2025, the stock increased by 10.56% in the past month and 20.51% over the past three months, but decreased by 17.03% over the last 12 months with a year-to-date return of -24.38%. The share price as of October 20, 2025, was $32.41, a decline of 19.98% from $40.50 on October 21, 2024. A notable event was the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners for up to $60 million in cash, announced on October 8, 2025. An insider bought US$289k worth of stock on August 15, 2025, and Enovis reported beating Q2 earnings and revenue estimates.

Specific demand seasonality information for Enovis Corp.'s products and services was not found. However, the medical technology industry can be influenced by healthcare spending cycles, elective procedure volumes, and new product introductions, which may have seasonal variations.

Enovis Corporation is a global medical technology company focused on developing clinically differentiated solutions to improve patient outcomes and restore motion. Established in 2022 after separating from Colfax Corporation, Enovis operates in the Healthcare sector, specifically the Medical Devices industry. The company operates through two segments: Prevention & Recovery, offering orthopedic solutions and recovery sciences products, and Reconstructive, focusing on surgical implants for joint reconstruction and surgical productivity tools. Major products and brands include DonJoy, Aircast, Exos, Procare, Compex, Chattanooga, and Enovis Surgical, with an emphasis on digitally enabled rehabilitation solutions.

Enovis Corporation has a significant global presence, with brands sold in over 50 countries through subsidiaries or distributors. The company has manufacturing, assembling, warehousing, and engineering facilities in Europe, Asia, South America, and the Middle East. Enovis maintains a direct presence in countries across the USA, Europe, Canada, South America, Asia Pacific, Central Europe, the Middle East, and South Africa. The company's headquarters are in Wilmington, Delaware, USA.

Enovis has focused on innovation and growth within the medical technology sector, particularly in digitally enabled rehabilitation solutions. The company earned the OMTEC Award for Bold Leadership in 2025. Enovis is committed to corporate social responsibility, including implementing eco-friendly practices and developing sustainable products. The company also invests in clinical research and training programs to support product adoption, surgical education, and patient outcomes.

Enovis Corporation's ownership is diverse, with institutional shareholders holding 98.45% of the stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, American Century Companies Inc, iShares Core S&P Small-Cap ETF (IJR), Dimensional Fund Advisors Lp, Davenport & Co LLC, Dorsey Asset Management, LLC and State Street Corp. Insider ownership accounts for 2.70% of the stock. Bdt Capital Partners LLC is the largest individual shareholder, owning 67.57 million shares, representing 118.22% of the company. Steven M. Rales is another significant insider, owning 10.55 million shares. In the past three months, Enovis insiders have bought more company stock than they have sold, with purchases totaling $374,760.00 and no sales.